- Conditions
- Hepatitis C
- Interventions
- TMC435
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Los Angeles, California • San Diego, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir, Placebo, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Oakland, California • San Diego, California + 23 more
- Conditions
- HIV, Hepatitis C, Infections
- Interventions
- Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 4
- States / cities
- Lancaster, California • Los Angeles, California
- Conditions
- Solid Cancers
- Interventions
- Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
- Conditions
- Essential Thrombocythemia
- Interventions
- INCA033989, Best Available Treatment
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Duarte, California • Greenbrae, California + 32 more
- Conditions
- Chronic Hepatitis B
- Interventions
- hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
- Biological · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Sofosbuvir, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Coronado, California • Los Angeles, California + 43 more
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 13 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic
- Interventions
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Pegylated Interferon/ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Hepatitis C, Medication Adherence
- Interventions
- enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
- Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hepatitis C
- Interventions
- PF-00868554, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Kidney Cancer
- Interventions
- pegylated interferon alfa
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- PEG-rIL-29, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- ZymoGenetics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Coronado, California • La Jolla, California + 26 more
- Conditions
- Genotype 1 Chronic Hepatitis C, Treatment Naive
- Interventions
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 34 more
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Anaheim, California • Coronado, California • San Jose, California + 7 more
- Conditions
- Hepatitis C
- Interventions
- Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,095 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
- Conditions
- Chronic Hepatitis B
- Interventions
- VIR-2218 and peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, Peg-IFN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 17 more